Back to top
more

Ascendis Pharma (ASND)

(Delayed Data from NSDQ)

$136.93 USD

136.93
376,771

-6.25 (-4.37%)

Updated Apr 25, 2024 04:00 PM ET

After-Market: $136.88 -0.05 (-0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (69 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Why Earnings Season Could Be Great for Ascendis Pharma (ASND)

by Zacks Equity Research

Ascendis Pharma (ASND) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Are Medical Stocks Lagging AdaptHealth (AHCO) This Year?

by Zacks Equity Research

Here is how AdaptHealth Corp. (AHCO) and Ascendis Pharma A/S (ASND) have performed compared to their sector so far this year.

Argenx (ARGX) Moves 11.2% Higher: Will This Strength Last?

by Zacks Equity Research

Argenx (ARGX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

The Zacks Analyst Blog Highlights Legend Biotech, Exact Sciences, Exelixis, Ascendis Pharma and MorphoSys

by Zacks Equity Research

Legend Biotech, Exact Sciences, Exelixis, Ascendis Pharma and MorphoSys are part of the Zacks top Analyst Blog.

Nalak Das headshot

5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024

by Nalak Das

We have narrowed our search to five biotech stocks with strong potential for 2024. These are MOR, LEGN, ASND, EXEL and EXAS.

Is AdaptHealth (AHCO) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how AdaptHealth Corp. (AHCO) and Ascendis Pharma A/S (ASND) have performed compared to their sector so far this year.

Ascendis Pharma A/S (ASND) is a Great Momentum Stock: Should You Buy?

by Zacks Equity Research

Does Ascendis Pharma A/S (ASND) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are Medical Stocks Lagging Ascendis Pharma (ASND) This Year?

by Zacks Equity Research

Here is how Ascendis Pharma A/S (ASND) and Autolus Therapeutics PLC Sponsored ADR (AUTL) have performed compared to their sector so far this year.

Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Zoetis' (ZTS) higher companion animal product sales are expected to have driven revenues in the fourth quarter of 2023, partially offset by declining livestock product sales.

Why Earnings Season Could Be Great for Ascendis Pharma (ASND)

by Zacks Equity Research

Ascendis Pharma (ASND) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Does Ascendis Pharma A/S (ASND) Have the Potential to Rally 51.72% as Wall Street Analysts Expect?

by Zacks Equity Research

The consensus price target hints at a 51.7% upside potential for Ascendis Pharma A/S (ASND). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zoetis (ZTS) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Higher sales of Zoetis' (ZTS) companion animal and livestock products are expected to have driven sales in the third quarter of 2023, partially offset by declining swine product sales.

Ascendis Pharma A/S (ASND) Loses -8.26% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

The heavy selling pressure might have exhausted for Ascendis Pharma A/S (ASND) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Femasys (FEMY) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Femasys' (FEMY) revenues in third-quarter 2023 are expected to have been driven by the higher international sales of its marketed products. Pipeline updates are expected over the earnings call.

Eton Pharma (ETON) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Eton Pharma's (ETON) revenues in the third quarter of 2023 are expected to have been driven by the sales of its marketed products.

Ascendis Pharma A/S (ASND) Soars 3.2%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Ascendis Pharma A/S (ASND) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Company News for Sep 7, 2023

by Zacks Equity Research

Companies In The News Are: AVAv, ASND, HQY, PLAB.

Wall Street Analysts Predict a 41.43% Upside in Ascendis Pharma A/S (ASND): Here's What You Should Know

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 41.4% in Ascendis Pharma A/S (ASND). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

How Much Upside is Left in Ascendis Pharma A/S (ASND)? Wall Street Analysts Think 47.35%

by Zacks Equity Research

The mean of analysts' price targets for Ascendis Pharma A/S (ASND) points to a 47.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Pfizer (PFE) Gets FDA Nod for Growth Hormone Deficiency Drug

by Zacks Equity Research

The FDA approves Pfizer (PFE) and OPKO Health's (OPK) Ngenla to treat growth hormone deficiency in pediatric patients. The drug's commercial launch is expected this August.

Ascendis Pharma A/S (ASND) Soars 8.5%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Ascendis Pharma A/S (ASND) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

The Zacks Analyst Blog Highlights bluebird, Oncternal Therapeutics, Avidity, Ascendis and Vertex Pharmaceuticals

by Zacks Equity Research

bluebird, Oncternal Therapeutics, Avidity, Ascendis and Vertex Pharmaceuticals are included in this Analyst Blog.

Biotech Stock Roundup: BLUE Announces Q4 Results, ONCT, ASND & RNA Fall on Updates

by Zacks Equity Research

Earnings and pipeline updates from bluebird bio (BLUE) and Avidity (RNA) are the key highlights for the biotech sector.

Ascendis (ASND) Down on Hypoparathyroidism Drug NDA Deficiencies

by Zacks Equity Research

The FDA identifies deficiencies in Ascendis' (ASND) regulatory filing for TransCon PTH in hypoparathyroidism. This might lead to an extended review timeline of the company's filing.

Omega Therapeutics, Inc. (OMGA) Moves 15.2% Higher: Will This Strength Last?

by Zacks Equity Research

Omega Therapeutics, Inc. (OMGA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.